德琪醫藥與默克合作在1期試驗中聯合Keytruda和ATG-037治療實體瘤
格隆匯12月27日丨德琪醫藥表示,已與默克(MRK.US)開展了一項全球臨牀合作,將ATG-037作為單一療法,進行與默克的重磅抗癌藥物Keytruda聯合用於局部晚期或轉移性實體瘤患者的一期臨牀試驗。這項被稱為STAMINA-001的研究的主要目標是確定二期試驗的適當劑量。德琪醫藥指出,ATG-037作為獨立治療的研究於2022年第二季度開始納入患者,並將於2023年納入與Keytruda的聯合治療。該公司補充説,患者登記目前正在澳大利亞進行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.